| Name | Title | Contact Details |
|---|---|---|
John Darden |
VP of Marketing | Profile |
Kristen Summers |
Director, Clinical Supply Chain | Profile |
Jen Lustig |
Executive Director of Human Resources | Profile |
Uromedica, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology.
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis.
Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem`s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.